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We assessed the prevalence of TNFRSF13B mutations and the clinical correlates in an Italian cohort of 189 CVID, 67 IgAD
patients, and 330 healthy controls to substantiate the role of TACI genetic testing in diagnostic workup. We found that 11% of
CVID and 13% of IgAD carried at least one mutated TNFRSF13B allele. Seven per cent of CVID had monoallelic-mutations and
4% had biallelic-mutations. The frequency of C104R monoallelic-mutations was not higher than that found in healthy controls.
Biallelic-mutations were exclusively found in CVID. CVID patients carrying monoallelic-mutations had an increased prevalence
of lymphadenopathy, granulomata, and autoimmune cytopenias. CVID carrying biallelic-mutations had a low prevalence of
autoimmunity in comparison with TACI wild-type CVID. Moreover, biallelic-mutated CVID had higher frequency of switched
memory B-cells and higher IgM and IgA antibodies to polysaccharide antigens than TACI wild-type and monoallelic-mutated
CVID. TACI-mutated IgAD patients had only monoallelic-mutations and did not display clinical difference from IgAD wild-type
patients. In conclusion, TNFRSF13B genetic screening of antibody deficiencies may allow the identification of mutational patterns.
However, as with counseling for risk assessment, geneticists should be aware that the interpretation of genetic testing for TACI
mutations is difficult and the potential impact on clinical management is still limited.
1. Introduction
Defects in antibody production predisposing to various
types of infections are the hallmark of primary antibody
deficiencies (PADs) [1, 2]. Genetic defects underlying PADs
remain unknown in the majority of cases. Recently, the
European ESID Registry has defined Working Definitions
for Clinical Diagnosis of PAD entities for patients without
genetic diagnosis including Common Variable Immunode-
ficiency Disorders (CVID), the most common symptomatic
antibody deficiency, and Selective IgA Deficiency (IgAD)
(http://esid.org/). In the absence of genetic mutation(s) these
criteria are based on clinical and immunological abnormal-
ities, allowing a “possible” and not a “definitive” diagnosis.
The clinical spectrum of PADs varies between different
entities and even within the same entity, ranging from severe
disease with a reduced life expectancy, to very mild or even
asymptomatic forms. ForCVID the clinical phenotype ranges
from a poorly symptomatic one to severe phenotypes char-
acterized by high susceptibility to infections, autoimmunity,
granulomatous inflammation, lymphoproliferative disorders,
and malignancies [3–8].
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Immunologic abnormalities in patients with CVID
include defects of B-cell survival, decreased frequency of cir-
culating CD27+ memory B-cells, failure of isotype switching
to IgA and IgG, defective B-cell activation, and inability to
mount responses to polysaccharide antigens [9].
The search for causative or susceptibility gene(s) is pro-
gressing and rare autosomal recessive mutations in a number
of single genes have recently been reported in CVID [8].
In particular, mutations in the TNFRSF13B gene encoding
TACI, a tumor necrosis factor receptor superfamily member
expressed on B-cells, have been reported in 7–10% of CVID
patients [10–12]. Similarly, TACI mutations have also been
observed in IgAD [10, 11, 13, 14]. TACI can bind two ligands, a
proliferation-inducing ligand (APRIL) and B-cell-activating
factor (BAFF) [15], and is critical for B-cell homeostasis
and function. TACI is essential for the establishment of
central B-cell tolerance, given that all subjects carryingC104R
and A181E missense TNFRSF13Bmutations have an inability
to remove developing autoreactive B-cells in bone marrow
[16]. Intracellular TACI domains interact with several sig-
naling molecules, including myeloid differentiation factor
88 (MyD88) gene, as well as activated endosomal toll-like
receptor (TLR) 7 and TLR9 [17, 18].
Several papers have analyzed the pathogenic role of
TNFRSF13B mutations in B-cell function, development, and
tolerance.TNFRSF13B haploinsufficiency or null alleles result
in decreased TACI expression on memory B-cells and
impaired antibody secretion, suggesting that during later
stages of B-cell development, TACI supports class-switch
recombination, plasma cell differentiation, and antibody
secretion [19, 20].
The role of TACI in T cell-independent antibody response
is controversial [21–24]. For the majority of the authors the
knockout of TNFRSF13B gene in mice results in an impaired
T cell-independent type II (TI-2) response and virtually
abolishes APRIL-induced switching to IgA, IgE, and IgG1
[21, 22]. In addition, TACI−/− mice spontaneously develop
lymphoproliferation and a lethal autoimmune syndrome
[25].
Many cohort studies have screened PAD patients for
TACI mutations [12, 13, 26–28], mainly in exons 3 and 4
because the vast majority of all detected mutations, including
a C104R mutation that alters ligand binding and the A181E
mutation that affects transmembrane function [29, 30], occur
in these exons. Compound heterozygotes and homozygotes
have been identified, but in the majority of cases TNFRSF13B
mutations are present as simple heterozygous variants. There
is a general agreement that, in CVID, monoallelic mutations
are associated with autoimmunity and lymphoproliferation
phenotype [12, 16], while few studies have addressed the issue
of TACI mutations and their clinical significance in IgAD
[13, 14, 31]. The clinical and immunological associations of
biallelic TACI mutations are less clear [13]. At present, it
is doubtful whether detection of TACI mutations could be
helpful for early diagnosis and prognosis in affected patients.
In our study, we examined the prevalence of TACI mutations
and their clinical correlates in a population of Italian CVID
and IgAD patients, in order to evaluate whether screening
for TACI mutations should be recommended as part of the
genetic diagnostic workup and genetic counseling.
2. Methods
2.1. Patients. We enrolled 256 adult Caucasian patients with
PADs diagnosed according to ESID criteria [1], 189 of whom
were affected by CVID and 67 by IgAD. Patients were attend-
ing the clinics for Primary Immunodeficiencies from four
Italian cities: Rome, Naples, Ancona, and Bologna. We also
included in the study 330Caucasian anonymous healthy adult
donors >50 years old, recruited from Italian Blood Donor
Centers. Relevant clinical and immunological data were col-
lected from medical files, including serum immunoglobulin
(Ig) levels at diagnosis, clinical history of recurrent infec-
tions, chronic diarrhea, bronchiectasis, autoimmune diseases
(autoimmune hemolytic anemia (AHA), idiopathic throm-
bocytopenic purpura (ITP), vitiligo, arthritis, coeliac disease
(CD), insulin dependent diabetes mellitus (IDDM), atrophic
gastritis, inflammatory bowel diseases (IBD)), lymphoprolif-
erative disorders (splenomegaly, lymph nodes enlargement,
and granulomatous disease), and cancers. For CVID patients
only, laboratory assessment of the frequency of T cell and B-
cell subsets and the response to pneumococcal polysaccha-
ride antigens were collected. The institutional review board
approved the study and a signed informed consent was
obtained from all participants.
2.2. Sequence Analysis of TNFRSF13B. PCR amplification and
sequencing of TNFRSF13B exons and splicing junctions were
performedwith primers and conditions as described in Salzer
et al. [10]. Sequence analysis was performed using Sequencer
version 5.0 (Gene Codes Corporation, AnnArbor,MI, USA).
To estimate the pathogenic effect of the described
TNFRSF13Bmutations on protein structure and function, we
employed web-based in silico software tools. The impact of
mutations on protein structure was assessed with PolyPhen2
(http://genetics.bwh.harvard.edu/pph2/) and on splicing
with Human Splicing Finder 3.0 (http://www.umd.be/HSF3/
HSF.html).
2.3. Flow Cytometry Analysis. Peripheral bloodmononuclear
cells were obtained by density-gradient centrifugation.
Immunophenotyping was performed with a combination
of 4 fluorochrome-labeled monoclonal antibodies (BD
Biosciences). The following B-cell populations were
analyzed: classical na¨ıve (CD19+CD27−CD21+CD38+),
switched memory (CD19+CD27+CD21+IgM−),
IgM memory (CD19+CD27+IgM+IgD+), and
transitional (CD19+IgM++CD38++) and CD21 low
(CD19+CD21−/lowCD38−). The following T cell subsets
were analyzed: CD4 (CD3+CD4+), CD8 (CD3+CD8+), CD4
memory (CD4+CD45RO+), CD4 na¨ıve (CD4+CD45RA+),
and CD4 Treg (CD4+CD25highCD127−). Dead cells were
excluded from analysis by side/forward scatter gating. FACS
analyses were performed on a FACSCalibur instrument (BD
Biosciences) using Cell Quest (BD) and FlowJo (Tree Star)
software.
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2.4. 23 Serotype-Specific Anti-Pneumococcal Polysaccharide
IgM and IgA Antibodies. IgM and IgA antibodies to 23 PS
serotypes were quantified using a new ELISA test PS23
IgA and PS23 IgM ELISA, modified from the commercially
available PS23 Pneumococcal Capsular Polysaccharide IgG
VaccZyme ELISA, as described in our previous papers [32,
33].
2.5. Statistical Analysis. Statistical analysis was performed
with dedicated software (StatView, GraphPad). Descriptive
data are presented as mean and standard deviation (SD).
The statistical significance of differences in the frequencies
of mutations and polymorphisms between groups was eval-
uated using two-tailed Fisher’s exact test. Comparison of
clinical features between groupswas performed by theMann-
Whitney test. Comparison of categorical and noncontinuous
variables between groups was performed by Fisher’s exact
test. Comparison of polysaccharide antibodies before and
after immunization was performed by the Wilcoxon test. A
𝑝 value of <0.05 was taken as the threshold of statistical
significance.
3. Results
3.1. Clinical Characteristics of the PAD Population
(a) CVIDPatients. One hundred eighty-nine (92males and 97
females) CVID patients were enrolled in the study.Themean
age at the time of the study was 51 ± 15.6 years. Immunoglob-
ulin levels at diagnosis were IgG 272 ± 153mg/dL; IgA 25 ±
31mg/dL; and IgM 73± 170mg/dL. At the time of the study all
patients were on Ig replacement therapy and their serum IgG
trough level was 682 ± 195mg/dL. One hundred five (56%)
patients had previously almost one episode of pneumonia, 85
(45%) had bronchiectasis, and 47 (25%) had chronic diarrhea.
Fifty patients (27%) had at least one autoimmune man-
ifestation: 7% had AHA, 12% had ITP, and 18% had other
autoimmunemanifestations (including vitiligo, arthritis, CD,
IDDM, atrophic gastritis, and IBD). Signs of lympho-
proliferative disorders were found in 114 patients (60%):
splenomegaly was found in 59% of patients, lymph nodes
enlargement in 28%, and granulomatous disease in 15%.
Eighty-five patients had bronchiectasis (45%) and 47 patients
(25%) had chronic diarrhea.Thirty-three patients (17.5%) had
a diagnosis of cancer and three patients had more than one
cancer: 12 patients had B-cell non-Hodgkin lymphoma; two
patients had splenic lymphoma; 6 patients had gastric ade-
nocarcinoma, two patients had colorectal adenocarcinoma,
and 15 patients had other cancers. Among the 189 patients,
180 cases were sporadic and 9 were familiar from 5 families.
(b) IgAD Patients. Sixty-seven IgAD patients (44 males and
23 females) with mild symptomatic upper respiratory tract
infections were enrolled. The mean age at the study time was
11.3 ± 10.6 years. Immunoglobulins levels at diagnosis were
IgG 1372.9 ± 333.1mg/dL; IgA 6.5 ± 8.2mg/dL; IgM 119.0 ±
41.7mg/dL. Sixteen patients (24%) had at least one autoim-
mune manifestation, including CD (7 patients), tiroiditis (4
patients), juvenile idiopathic arthritis (1 patients), IDDM (1
patient), and vasculitis (1 patient). None had autoimmune
cytopenias or signs of neither lymphoproliferative disorders
nor cancer.
Among the 67 index patients, 55 cases were sporadic and
12 were familial from 5 families.
3.2. TNFRSF13B Genetic Analysis of the PAD Population. We
found that 30/256 PAD patients (11.8%) carried at least one
TNFRSF13B variant (Figures 1(a) and 1(b) and Table 1).
Twenty-one CVID patients (11.1%) carried at least
one TNFRSF13B variant. Monoallelic mutations were
found in 13 patients (6.9%): 4 patients (2.3%) carried
the heterozygous C104R mutation and 9 patients
(5.1%) had non-C104R monoallelic mutations. Eight
patients (4.5%) carried biallelic mutations including one
patient carrying the C104R homozygous variant. Seven
patients carried compound heterozygous mutations:
[L69TfsX12];[R72H], [I87N];[Y164X], [I87N];[A181E],
[C104R];[C193X], [C104R];[A181E], [Y164X];[A181E], and
[S144X,C193X];[Y102X] (Table 1(a) and Figure 1).
Nine IgAD patients (13.4%) carried a single TNFRSF13B
variant: 3 patients (4.7%) were sibs and had the heterozy-
gous C104R mutation and 6 patients (9.4%) carried non-
C104R monoallelic mutations. None of the IgAD patients
had biallelic mutations (Table 1(b)). A total of 330 controls
were analyzed for sequence variants in TNFRSF13B. Two of
them (0.9%) were heterozygous for the C104R variant and
one (0.4%) was heterozygous for the I87N allele. No other
monoallelic or biallelic missense mutations were found in
healthy controls.
The frequency of TNFRSF13B gene mutations was signif-
icantly higher in CVID compared to healthy controls (𝑝 <
0.0001), with the exception of monoallelic C104R mutations
(𝑝 = ns) (Table 1(a)). The frequency of TACI mutations was
significantly higher in IgAD compared to healthy controls,
either including or not the three sibs carrying the C104R
mutation (𝑝 = 0.0001 and 𝑝 = 0.0005, resp.) (Table 1(b)).
Among PADpatients carrying variants, 25 were unrelated
and 5 belonged to two different families: three sibs with
IgAD were heterozygous for C104R and two sibs with CVID
were heterozygous for I87N. In both cases the mutation was
inherited from one unaffected parent.
Seventeen different genetic alterations were observed,
one of which has not been previously described: a novel
nonsynonymous G190A variant found in an IgAD patient.
The polymorphisms V220A (rs56063729, MAF 0.016) and
P251L (rs34562254, MAF 0.139) were observed in the cohort
of antibody-deficient patients at frequencies that were not
significantly different from those observed in healthy control
populations.
All the nonsynonymous variants, with the exception of
G190A, were present in dbSNP with a MAF ranging from
<0.0001 to 0.005 (Table 2).The possible impact of each amino
acid substitution on structure and function of the protein
was predicted using PolyPhen2. All the missense variants
were predicted to be damaging with a score ranging from
0.474 to 1.000, with the exception of R72H, predicted to be
benign with a score of 0.003. The Human Splicing Finder
3.0 tool predicted that the nucleotide substitution leading
4 Journal of Immunology Research
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Figure 1: Distribution of TNFRSF13B mutations across the TACI protein in 21 of 189 patients with CVID (a) and in 9 of 67 patients with
IgAD (b). Each symbol represents one patient. e indicates patients with homozygous TNFRSF13B mutations; ∘ represents patients with
heterozygous TNFRSF13Bmutations. Compound heterozygous mutated TACI-deficient patients are labeled as indicated in the figure. CRD1
and CRD2 indicate cysteine-rich domains (residues 32–68 and 69–107); TM, transmembrane domain (residues 160–182).
to Arg > His amino acid change at the position 72 of the
protein (c.215 G > A) broke an Exonic Splicing Enhancer
(ESE) binding site for SF2/ASF protein located at the position
+11 to +17 from the exon 3 junction, potentially altering the
splicing of the corresponding exon. Hence, we decided to
include the compound heterozygous patient, carrying both
R72H and L69TfsX12 variants (I.74 in Table 3), in the group
of patients with biallelic genetic alterations. All missense
mutations are classified by ClinVar as Variants of Uncertain
Significance (VUS), with the exception of C104R and A181E
whose pathogenicity has already been proven.
3.3. Clinical Phenotypes Observed in TACI-Mutated CVID.
Clinical details of 21 TACI-mutated CVID patients are
reported in Table 3. A summary of the frequency of clinical
manifestations is reported in Table 4.
(a) Monoallelic TNFRSF13B Mutations. As already demon-
strated [12, 34] CVIDpatients carryingTNFRSF13B heterozy-
gous mutations had a higher prevalence of autoimmunity
compared with patients with wild-type TNFRSF13B (61.5%
versus 23%,𝑝 = 0.005) (Figure 2(a)). Autoimmune cytopenia
was themost common autoimmune phenomenon in patients
Journal of Immunology Research 5
Table 1: Frequencies, significance, and relative risk of TNFRSF13B mutations in 189 CVID (a) and in 67 IgAD (b) Italian patients compared
with healthy controls.
(a) CVID
Patient subset (𝑛) Genotype 𝑁 (%) 𝑝∗ Relative risk(95% CI)
All patients (189) Any mutation 21 (11.1%) <0.0001 8.5 (2.6–28.1)
Patients with biallelic mutations excluded
(181) Monoallelic mutations 13 (7.2%) 0.0034 5.5 (1.56–19.0)
Patients with biallelic and C104R
mutations excluded (177)
Monoallelic mutations
excluding C104R 9 (5.1%) 0.0061 11.6 (1.5–91.0)
Patients with monoallelic mutations
excluded (176) Biallelic mutations 8 (4.5%) 0.0012 21.9 (1.3–376.9)
Patients without mutations other than
heterozygous C104R (172) Heterozygous C104R 4 (2.3%) 0.4084 2.7 (0.5–14.4)
(b) IgAD
Patient subset (𝑛) Genotype 𝑁 (%) 𝑝∗ Relative risk(95% CI)
All IgAD patients (67) Any mutation 9 (13.4%) 0.0001 10.3 (2.9–37.0)
Patients without mutations other than
heterozygous C104R (64)
Monoallelic mutations
excluding C104R 6 (9.4%) 0.0005 21.4 (2.6–174.3)
Patients without mutations other than
heterozygous C104R (61) Heterozygous C104R 3 (4.9%) 0.0064 5.6 (1.0–33.0)
∗Two-tailed 𝑝 values calculated by Fisher’s exact test.
Table 2: Summary of the nonsynonymous variants identified in patients with CVID and IgAD.
Variants dbSNP MAF (ExAC)∗ ClinVar PolyPhen score
D41G rs763197017 T < 0.0001 VUS∗∗ 0.995, probably damaging
R72H rs55916807 T = 0.0017 VUS 0.003, benign
I87N rs72553877 T < 0.0001 VUS 0.986, probably damaging
C104Y rs72553879 A < 0.0001 VUS 1.000, probably damaging
C104R rs34557412 C = 0.003 Pathogenic allele 1.000, probably damaging
P151L rs200037919 A < 0.0001 VUS 0.728, possibly damaging
C172Y rs751216929 A < 0.0001 VUS 0.985, probably damaging
A181E rs72553883 A = 0.005 Pathogenic allele 0.890, possibly damaging
G190A Not described n.d. VUS 0.989, probably damaging
R202H rs104894649 A < 0.0001 VUS 0.474, possibly damaging
MAF: minor allele frequency.
∗MAF source: Exome Aggregation Consortium (ExAC).
∗∗VUS: Variants of Uncertain Significance.
with heterozygous TNFRSF13B mutations. CVID patients
with monoallelic TACI mutations had a higher frequency
of autoimmune cytopenias than TACI wild-type patients
(54% versus 13%, 𝑝 < 0.0001); in particular, patients with
TNFRSF13B C104R mutations had a higher prevalence of
ITP (50% versus 10%, 𝑝 = 0.05), whereas patients with
non-C104R TNFRSF13Bmutations had a higher frequency of
AHA (44% versus 5%, 𝑝 = 0.002). The overall prevalence of
lymphoproliferativemanifestations was similar amongCVID
groups (Figure 2(b)). However, lymph node enlargement and
granulomatous diseases were more frequently observed in
monoallelic TACI-mutated CVID compared to wild-type
CVID (54% versus 25%, 𝑝 = 0.04 and 38% versus 11%,
𝑝 = 0.02, resp.). No difference was observed between
TACI wild-type CVID and CVID carrying monoallelic TACI
mutations on the frequencies of infective manifestations,
including pneumonia, chronic diarrhea, and the presence of
bronchiectasis.
(b) Biallelic TNFRSF13B Mutations. No clinical differences
were observed between CVID carrying TNFRSF13B biallelic
mutations and wild-type. In particular, the prevalence of
autoimmunity was similar between the groups (25% ver-
sus 23%, 𝑝 value being nonsignificant) (Figure 2(a)). No
difference was observed between patients carrying bial-
lelic or monoallelic TACI mutations on the presence of
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Table 4: Frequencies of clinical complications in patients with wild-type and TACI-mutated CVID.
Wild-type
𝑛 = 168
TACI mutated
𝑛 = 21
𝑝 value
Autoimmunity, 𝑛 (%) 39 (23) 10 (48) 0.03
Autoimmune cytopenia 22 (13) 9 (43) 0.002
Other autoimmune manifestations 27 (16) 3 (14) ns
Lymphoproliferation, 𝑛 (%) 101 (60) 15 (71) ns
Splenomegaly 96 (57) 14 (67) ns
Lymphadenopathy 41 (25) 10 (48) 0.03
Granulomatous disease 19 (11) 6 (29%) 0.04
Malignant lymphoproliferation 15 (19) 1 (4%) ns
Cancer, 𝑛 (%) 27 (20) 4 (17) ns
Bronchiectasis, 𝑛 (%) 72 (43) 10 (53) ns
Chronic diarrhea, 𝑛 (%) 42 (25) 5 (25) ns
bronchiectasis and on frequencies of infective manifesta-
tions (episode of pneumonia/chronic diarrhea). A malig-
nant lymphoproliferative disease was recorded in a single
TACI-mutated CVID patient suffering from indolent B-cell
non-Hodgkin lymphoma and carrying biallelic mutations
[L69TfsX12];[R72H].
3.4. Immunological Phenotype and Immunoglobulin Levels in
CVID TACI-Mutated Patients
(a) Monoallelic TNFRSF13B Mutations. A severe B-cell lym-
phopenia (<1%) was identified only in one TACI-mutated
patient (C193X).The frequency of IgM−IgD−CD27+ switched
memory B-cells was similar in CVID carrying monoallelic
TACI mutations and in TACI wild-type (5.6% ± 4.4 versus
3.4% ± 5), while the frequency of IgD+IgM+CD27− na¨ıve
B-cells was lower (53.8% ± 33.6 versus 76.2% ± 19.2, 𝑝 =
0.01). Among TACI-mutated patients, the group carrying a
non-C104R heterozygous mutation had the lowest B na¨ıve
frequency compared to wild-type subjects (37.5% ± 53). No
differences were found in the frequency of CD21low cells.
Overall, TACI-mutated patients had a lower frequency of
Treg cells than CVID wild-type subjects (1.7% ± 1.3 versus
2.9% ± 2.2, 𝑝 = 0.04). In particular, the group carrying non-
C104R heterozygous TACI mutations had the lowest Treg
subset frequency (0.1% ± 0.1, 𝑝 = 0.05). No difference was
observed between CVID with TACI wild-type sequence and
CVID carrying biallelic mutations on the frequency of other
T cells subsets. Immunophenotype data are summarized in
Figure 3(a).
Serum immunoglobulin levels at diagnosis were similar
in TACI-mutated and TACI wild-type CVID (Figure 3(b)).
The group carrying non-C104R TNFRSF13B mutations had
the lowest IgA levels compared to wild-type subjects (25.2 ±
31.3 versus 6.8mg/dL ± 5.5, 𝑝 = 0.04).
(b) Biallelic TNFRSF13B Mutations. Biallelic TACI-mutated
CVID had higher frequency of switched memory B-cells
compared to TACI wild-type CVID patients (9.25% ± 3.8
versus 3.5 ± 5.0, 𝑝 = 0.03) but similar frequency of
na¨ıve B-cells. Biallelic TACI-mutated CVID had also higher
frequency of switched memory B-cells in comparison with
patients with monoallelic TACI mutations (3.5% ± 3.3, 𝑝 =
0.03). No differences were found in the frequency of other
B-cell subsets (data not shown). Moreover, patients carrying
two mutated TNFRSF13B alleles had higher IgA levels than
TACI wild-type CVID (25.2mg/dL ± 31.3, 46.3mg/dL ± 35.7,
𝑝 = 0.05).
3.5. Antibody Response to Pneumococcal Polysaccharide Anti-
gens in CVID. Due to the fact that all patients were under IgG
replacement at the time of the study, we analyzed IgMand IgA
antibodies to 23-valent polysaccharide antigens. At baseline,
CVID patients carrying biallelic TNFRSF13B mutations had
higher IgM anti-23-valent polysaccharide antigens compared
to wild-type CVID patients (19.2U/mL ± 7.0 versus 3.8U/mL
± 7.1, 𝑝 = 0.01) and compared to CVID carrying monoallelic
TNFRSF13B mutations (3.9U/mL ± 9.1, 𝑝 = 0.05). The
same was observed for specific IgA: CVID patients carrying
biallelic mutations had higher prevaccination IgA anti-23-
valent polysaccharide antigens compared to wild-type CVID
(7mU/mL ± 8 versus 0.3mU/mL ± 0.8, 𝑝 < 0.0001).
As expected, all CVID patients had a low vaccination
response. Only biallelic-mutated patients had a significant
increase in postvaccination IgM and IgA titers (24.0U/mL ±
2.5, 𝑝 = 0.05; 15mU/mL ± 14, 𝑝 = 0.05, resp.)
while CVID carrying monoallelic-mutated or wild-type
TNFRSF13B sequences had amild but not significant increase
of specific IgM (8.0U/mL ± 12.1 and 5.0 ± 8.2, resp.) and of
specific IgA (0.5mU/mL ± 0.9 and 1.5mU/mL ± 5, resp.).
3.6. Clinical Phenotypes and Serum Immunoglobulin Levels in
TACI-Mutated IgAD. We found no differences in the spec-
trum of clinical manifestations between IgAD patients carry-
ing TACI mutations and those with wild-type TACI. Clinical
details of 9 TACI-mutated IgAD patients are reported in
Table 5. Serum immunoglobulin levels at diagnosis were
similar in TACI-mutated and wild-type TACI IgAD.
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Figure 2: Autoimmune (a) and lymphoproliferative (b) complications in patients with TACI wild-type or mutated sequence. TACI-deficient
individuals were grouped as carrying monoallelic TACI mutations (heterozygous C104R and heterozygous non-C104R) and biallelic TACI
mutations.
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Figure 3: Immunological phenotype (a) and immunoglobulin levels (b) in TACI-deficient individuals and wild-type TACI patients. TACI-
deficient individuals were grouped as carryingmonoallelic TACImutations (heterozygous C104R and heterozygous non-C104R) and biallelic
TACI mutations. The grey area represents the referral values (http://www.ipidnet.org/).
4. Discussion
TACI mutations have been identified in patients affected by
a variety of clinical conditions including primary antibody
deficiencies, sarcoidosis, and tonsillar hypertrophy [35]. In
PADs, TACI has been analyzed in several cohorts from
different geographical areas and mainly in CVID patients
among whom the prevalence of mutations is 5–10%. Con-
sidering only mutations in exons 3 and 4, genetic alterations
were found in about 10% of the CVID patients and in
about 5% of the IgAD patients, significantly more than in
the corresponding general population. We found a higher
12 Journal of Immunology Research
rate of TACI mutations ranging from 11.1% in CVID to
13.4% in symptomatic IgAD. The calculated relative risk was
also higher ranging from 8.5 (CVID) to 10.3 (IgAD). In
the two PAD groups, the majority of TACI mutations were
monoallelic, with heterozygous C104R accounting for 2.3%
(CVID) and 4.9% (IgAD). Surprisingly, in our series the fre-
quency of monoallelic C104R mutation was not significantly
different to that found in the cohort of Italian healthy donors
while the frequency of autoimmune and lymphoproliferative
signs overlapped that reported in the literature in CVID
patients withmonoallelic C104Rmutations [12]. In summary,
in Italian PADs we found pattern of TACImutations different
from other studies showing that ninety percent of all CVID
associated TNFRSF13Bmutations consist of either the C104R
mutation, which alters ligand binding, or the A181Emutation
that affects transmembrane function [30, 36].
The link to IgA deficiency is controversial. When first
reported, TACI mutations were associated with CVID and
IgA deficiency [10, 11] and a significant association ofmutated
TNFRSF13B gene and IgAD was later seen in other patients
cohort [13]. On the other hand, Pan-Hammarstro¨m et al.
showed that the TNFRSF13B variants have only minor roles,
if any, in the development of selective IgAD [31]. IgAD
may be an asymptomatic condition; therefore, establishing a
prevalence of TNFRSF13B gene mutations in IgAD patients
is challenging.The IgAD population described here included
only symptomatic patients. In this case, a significant asso-
ciation of mutated TNFRSF13B gene and IgAD was strictly
dependent on the choice of the healthy donors population.
We have recruited healthy adult donors from Blood Donor
Centers and we have chosen individuals >50 years old, in
order to reduce the risk of the presence of an asymptomatic
form of PAD.We found that near 4% of Italian CVID carried
biallelic TNFRSF13B mutations. Moreover, we confirmed
the previous data that TACI biallelic mutations are found
only in CVID [12]. Thus, from the genetic point of view,
the presence of biallelic mutations might correspond to a
definitive diagnosis of CVID. However, from the clinical
point of view, the analysis of clinical phenotypes confirmed
the proposition that “two mutations are better than one”
[16, 37]. In fact, patients with biallelic TACI mutations had a
similar incidence of autoimmunity and lymphoproliferation
signs compared to wild-type TACI patients, endorsing the
hypothesis that if monoallelic TACI mutations reduce the
elimination of autoreactive B-cells during the establishment
of central B-cell tolerance, biallelic TACImutations repress B-
cell activation, preventing the development of autoimmunity.
As shown by Salzer et al. [12], we confirmed that CVID
patients carrying biallelic TACI mutations had higher rel-
ative frequency of switched memory B-cells. Moreover, we
observed that biallelic TACI-mutated CVID patients had
higher IgA serum levels at diagnosis and higher prevacci-
nation and postvaccination IgM and IgA anti-pneumococcal
polysaccharide antigens. Here, we analyzed the IgM- and
IgA-mediated responses to TI-2 antigens. To the best of
our knowledge, no data are available about TI-2 humoral
response in humans carrying TACI mutations. Actually, in
animal models the role of TACI in TI-2 antibody responses
remains controversial. In murine knockout models, TACI is
required for TI antibody responses to bacterial-associated
polysaccharides [21–23] but is not crucial for TI antibody
responses to whole bacteria [24]. Our data suggest that in
biallelic-mutated CVID TI-2 antibody response is poor but
less affected than in TACI monoallelic-mutated CVID. This
was also confirmed by the observations that CVID carrying
two TACI mutations did not show more severe and more
recurrent infective manifestations than CVID having a TACI
wild-type and monoallelic-mutated sequence.
Further studies are needed to unravel the additional
genetic and environmental factors acting in concert with
biallelic genetic alterations in TNFRSF13B to give rise to
antibody deficiencies in humans.
Interestingly, the majority of patients with TACI-mutated
PAD had monoallelic mutations non-C104R, detected in five
per cent of CVID patients and about nine per cent of IgAD
patients. CVID patients carrying monoallelic non-C104R
mutations had a severe clinical phenotype with the highest
prevalence within the CVID groups of autoimmunity, AHA,
lymph nodes enlargement, and granulomatous diseases.
These clinical features were associated with immunological
abnormalities such as a low frequency of naı¨ve B-cells, very
low IgA serum levels, and a very low frequency of T regula-
tory cells. This last observation confirms already published
data showing that defects in peripheral B-cell tolerance in
monoallelic TACI-mutated CVID patients correlated with
elevated plasma BAFF concentrations and decreased Treg
frequencies [16]. These data further support the demonstra-
tion that defects in peripheral B-cell tolerance are correlated
with altered T regulatory (Treg) cell frequency and function,
a finding associated with clinical autoimmunity in CVID
patients [38]. Thus, in comparison with other published data
our cohort had a lower number of patients with monoallelic
C104Rmutation, a higher number of CVID patients carrying
monoallelic mutations non-C104R, and a higher number of
patients with compound heterozygous mutations.
The major challenge in diagnostic testing concerns the
interpretation of the unknown variants, the so-called “Vari-
ants of Uncertain Significance” (VUS). As shown in Table 2,
the majority of nonsynonymous variants of TACI are VUS.
This stresses the importance of appropriate pretest counseling
and informed consent by knowledgeable genetics profession-
als.
Despite consolidated evidence for a pathogenic role of
specific TNFRSF13Bmutations, such as C104R and A181E, in
B-cell tolerance [16] and impaired antibody production due
to haploinsufficiency during the later stages of B-cell devel-
opment [20], further work is required to identify additional
genetic hits and their potential clinical impact. This suggests
caution in the introduction of TACI genetic analysis in the
diagnostic workup of PAD.
In conclusion, TNFRSF13B genetic screening of hypo-
gammaglobulinemic patients may allow the identification of
novel mutational patterns, offering insight into the biological
mechanisms underlying the pathogenesis of PADs. However,
as with counseling for risk assessment, geneticists should be
aware of the fact that the interpretation of genetic testing
for TACI mutations is difficult and the potential impact on
clinical management is still limited.
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